|
Age:
|
|
• 0–10 years:
|
–
|
–
|
1
|
0.1%
|
0.317
|
|
• 11–20 years:
|
15
|
1.5%
|
149
|
14.9%
|
< 0.00001
|
|
• 21–30 years:
|
83
|
8.3%
|
128
|
12.8%
|
0.001
|
|
• 31–40 years:
|
333
|
33.3%
|
187
|
18.7%
|
< 0.00001
|
|
• 41–50 years:
|
292
|
29.2%
|
177
|
17.7%
|
< 0.00001
|
|
• 51–60 years:
|
125
|
12.5%
|
163
|
16.3%
|
0.016
|
|
• 61–70 years:
|
107
|
10.7%
|
132
|
13.2%
|
0.085
|
|
• 71–80 years:
|
55
|
5.5%
|
63
|
6.3%
|
0.448
|
|
- Mean:
|
43
|
34
| |
|
- Standard deviation (SD):
|
19.6
|
17.9
| |
|
Sex (Male : Female):
|
62.5 : 37.5%
|
61 : 39 %
|
0.771
|
|
Pre-existing lung co-morbidity:
|
13
|
1.3%
|
42
|
4.2%
|
0.000073
|
|
• COPD:
|
7
|
0.7%
|
22
|
2.2%
|
0.005
|
|
• ILD:
|
–
|
–
|
5
|
0.5%
|
0.025
|
|
• TB:
|
–
|
–
|
1
|
0.1%
|
0.317
|
|
• Sarcoidosis:
|
4
|
0.4%
|
9
|
0.9%
|
0.164
|
|
• Lung cancer or metastatic process:
|
2
|
0.2%
|
5
|
0.5%
|
0.256
|
|
CT findings (at two weeks of infection):
|
|
• Ground-glass opacities with or without consolidations:
|
1000
|
100%
|
1000
|
100%
|
–
|
|
• Atoll sign:
|
84
|
8.4%
|
99
|
9.9%
|
0.245
|
|
• Bulls-eye or target sign:
|
–
|
–
|
2
|
0.2%
|
0.157
|
|
• Crazy-paving:
|
167
|
16.7%
|
222
|
22.2%
|
0.002
|
|
° Patchy lesions with inter-lobular septal thickening.
|
105
|
10.5%
|
142
|
14.2%
|
0.012
|
|
° Diffuse ground-glass with inter-lobular septal thickening.
|
62
|
6.2%
|
80
|
8%
|
0.117
|
|
Peri-lobular fibrosis
|
123
|
12.3%
|
173
|
17.3%
|
0.02
|
|
• Air-bubble or vacuolar sign:
|
19
|
1.9%
|
36
|
3.6%
|
0.02
|
|
• Cavitation (> 1 cm):
|
–
|
–
|
5
|
0.5%
|
0.025
|
|
• Air-way involvement:
|
–
|
–
|
33
|
3.3%
|
< 0.00001
|
|
° Head-cheese:
|
–
|
–
|
8
|
0.8%
|
0.005
|
|
° Bronchiectasis:
|
–
|
–
|
25
|
2.5%
|
< 0.00001
|
|
° Tree in bud nodules
|
1
|
0.1%
|
1
|
0.1%
|
1
|
|
• Lymph nodes (short axis > 1 cm):
|
22
|
2.2%
|
38
|
38%
|
0.036
|
|
• Pleural effusion:
|
5
|
0.5%
|
3
|
0.3%
|
0.479
|
|
• Pericardial effusion:
|
13
|
1.3%
|
33
|
3.3%
|
0.003
|
|
• Pneumo-mediastinum:
|
2
|
0.2%
|
7
|
0.7%
|
0.095
|
|
Post-infectious sequel or complications (after 1 month of infection):
|
|
• Residual ground-glass attenuation:
|
7/49
|
14.3%
|
41/122
|
33.6%
|
0.011
|
|
• Fibrosis:
|
3/49
|
6.1%
|
15/122
|
12.3%
|
0.234
|
|
• Residual head cheese:
|
–
|
–
|
5/122
|
4.1%
|
0.151
|
|
• Secondary air trapping only:
|
–
|
–
|
3/122
|
2.5%
|
0.268
|
|
Secondary fungal infection:
|
–
|
–
|
4
|
0.4%
|
0.045
|
|
COVID-19 reinfection:
|
–
|
–
|
1
|
0.1%
|
0.317
|
